Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)

Organon

Status and phase: Completed; Phase 3

Conditions: Hypercholesterolemia; Coronary Disease

Treatments: Drug: MK0653, ezetimibe; Drug: Comparator: ezetimibe, placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092612

0653-802

2004_040

Details and patient eligibility

About

The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.

Full description

The duration of treatment is 10 weeks.

Enrollment: 372 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with elevated cholesterol and coronary heart disease

Exclusion criteria

• Patients who have cholesterol levels within normal ranges as identified by the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind